Recent advances in natriuretic peptides in congestive heart failure

被引：69
作者：
Boerrigter, G [1 ]
Burnett, JC [1 ]
机构：
[1] Coll Med, Mayo Clin, Rochester, MN 55905 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2004年 / 13卷 / 06期
关键词：
cyclic guanosine monophosphate; heart failure; natriuretic pepticles; nesiritide; neurohumoral activation;
D O I：
10.1517/13543784.13.6.643
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed.
引用
收藏
页码：643 / 652
页数：10
相关论文
共 58 条
[41]   Placebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failure [J].
Northridge, DB ;
Currie, PF ;
Newby, DE ;
McMurray, JJV ;
Ford, M ;
Boon, NA ;
Dargie, HJ .
EUROPEAN JOURNAL OF HEART FAILURE, 1999, 1 (01) :67-72
[42]   Relaxant effect of human brain natriuretic peptide on human artery and vein tissue [J].
Protter, AA ;
Wallace, AM ;
Ferraris, VA ;
Weishaar, RE .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (05) :432-436
[43]   MOLECULAR-FORMS OF ATRIAL-NATRIURETIC-FACTOR IN NORMAL AND FAILING HUMAN MYOCARDIUM [J].
RODEHEFFER, RJ ;
NARUSE, M ;
ATKINSON, JB ;
NARUSE, K ;
BURNETT, JC ;
MERRILL, WH ;
FRIST, WH ;
DEMURA, H ;
INAGAMI, T .
CIRCULATION, 1993, 88 (02) :364-371
[44]  
RODEN RL, 1998, J CARD FAIL, V4, P19
[45]   Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial [J].
Rouleau, JL ;
Pfeffer, MA ;
Stewart, DJ ;
Isaac, D ;
Sestier, F ;
Kerut, EK ;
Porter, CB ;
Proulx, G ;
Qian, CL ;
Block, AJ .
LANCET, 2000, 356 (9230) :615-620
[46]   Mechanisms of disease - Hormones and hemodynamics in heart failure [J].
Schrier, RW ;
Abraham, WT .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :577-585
[47]   NO- and haem-independent activation of soluble guanylyl cyclase:: molecular basis and cardiovascular implications of a new pharmacological principle [J].
Stasch, JP ;
Schmidt, P ;
Alonso-Alija, C ;
Apeler, H ;
Dembowsky, K ;
Haerter, M ;
Heil, M ;
Minuth, T ;
Perzborn, E ;
Pleiss, U ;
Schramm, M ;
Schroeder, W ;
Schröder, H ;
Stahl, E ;
Steinke, W ;
Wunder, F .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (05) :773-783
[48]   NO-independent regulatory site on soluble guanylate cyclase [J].
Stasch, JP ;
Becker, EM ;
Alonso-Alija, C ;
Apeler, H ;
Dembowsky, K ;
Feurer, A ;
Gerzer, R ;
Minuth, T ;
Perzborn, E ;
Pleiss, U ;
Schröder, H ;
Schroeder, W ;
Stahl, E ;
Steinke, W ;
Straub, A ;
Schramm, M .
NATURE, 2001, 410 (6825) :212-215
[49]   A FUNCTIONAL-ROLE FOR ENDOGENOUS ATRIAL-NATRIURETIC-PEPTIDE IN A CANINE MODEL OF EARLY LEFT-VENTRICULAR DYSFUNCTION [J].
STEVENS, TL ;
BURNETT, JC ;
KINOSHITA, M ;
MATSUDA, Y ;
REDFIELD, MM .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (03) :1101-1108
[50]   Cardiac fibrosis in mice lacking brain natriuretic peptide [J].
Tamura, N ;
Ogawa, Y ;
Chusho, H ;
Nakamura, K ;
Nakao, K ;
Suda, M ;
Kasahara, M ;
Hashimoto, R ;
Katsuura, G ;
Mukoyama, M ;
Itoh, H ;
Saito, Y ;
Tanaka, I ;
Otani, H ;
Katsuki, M ;
Nakao, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (08) :4239-4244
123456